Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Nci-Data'
Nci-Data published presentations and documents on DocSlides.
NCI Experimental Therapeutics Clinical Trials Network
by tawny-fly
(ETCTN). Central IRB Education Day. 28 April 2015...
NCI-Molecular Analysis for Therapy Choice
by conchita-marotz
(NCI-MATCH / EAY131). A phase II precision medic...
NCI-Molecular Analysis for Therapy Choice
by phoebe-click
(NCI-MATCH or EAY131). Interim Analysis Results....
NCI Workshop: Issues in Post-Treatment Surveillance
by koa
Lalitha K. Shankar, MD, PhD,. Cancer Imaging Progr...
Individuals With ID/DD Who Communicate Nonverbally
by kamari239
Sarah Taub NCI Webinar Series: . January 28. th. ,...
Oncology Clinical Trials
by holly
Sylvia . O’Neill, . MD . Executive Di...
NCI ANALYSIS REPORT Larnique Sugick
by bency
The National Core Indicators™ (NCI™) program i...
NCI Training Funding OpportunitiesThe Government Can HelpSusan Perki
by evans
2 NCI Grant Funding for Trainees PredoctoralPostdo...
Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents
by gelbero
Jeff Moscow, MD. IDB, CTEP. Overall Process of NCI...
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events
by lois-ondreau
S. Percy Ivy, MD. Associate Chief, Senior Investi...
Pilot Collaboration Between
by briana-ranney
ETCTN UM1 and NCI-CC P30 programs . Jeff Moscow. ...
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events
by mitsue-stanley
S. Percy Ivy, MD. Associate Chief, Senior Investi...
Mapping the NCI Thesaurus and the Collaborative Inter-Lingu
by liane-varnes
Amanda Hicks. University of Florida. aehicks@ufl....
Example of drug development
by briana-ranney
Objectives of preclinical tests. Preclinical test...
NCI-Molecular Analysis for Therapy Choice
by olivia-moreira
NCI-Molecular Analysis for Therapy Choice (NCI-MAT...
NCI AIIMS - JHAJJAR STATUS AS ON 27.10.2016 Scaled
by mitsue-stanley
NCI AIIMS - JHAJJAR STATUS AS ON 27.10.2016 Scaled...
Consolidation Ownership Issues
by jamison826
9-. 2. General Overview. The following topics are ...
Pat Sheehan (VA) and Gary Morin (NIH NCI) talk about the relationship between the Section 508 Coord
by ethan907
Sections of the Rehabilitation Act of 1973. Pat jo...
Outcomes For Adults On The Autism Spectrum Receiving Services In 31 States:
by caroline
Putting . The Research In Context. Valerie J. Brad...
Cancer Grand Challenges Challenge consultation workshop
by paisley
24 October 2022. Agenda. Welcome. (5 minutes). C...
Concept for a new RFA
by amelia
‘ CASCADE ’: Global Clinical Trials Network t...
eloma Toward a New UnderstandingStatement Richard Klausner MD Dire
by pagi
in the marrow to mature or may travel to other par...
NCI P01: Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunot
by LittleMissPerfect
UW TRT . P01 . Overview. The First TRT PO1 Awarded...
Program Overview April 2014
by SkylineBabe
Tony Dickherber, Ph.D.. Program Director. Center f...
http ://http:// grants.nih.gov/training/careerdevelopmentawards
by jordyn
K Kiosk - Information about NIH . Career Developme...
Sri Lankan BMT project John Moore
by summer
Haematology Department. St. Vincents Hospital. Why...
New Mexico State University
by bery
Carlsbad Environmental Monitoring Research Center...
Table of Contents
by winnie
1. BACKGROUND INFORMATI ON ON NCI - PBCF - CCL229 ...
Collaboration Opportunities to Further Advance ITCR Platforms
by keywordsgucci
Tony Dickherber. NCI, Center for Strategic Scienti...
Basic Group Accounts – F1 Syllabus – Part 3
by dayspiracy
. Management Level – Paper . F2. Advanced Financ...
Supported Decision-Making:
by missroach
International Context and Exploration of Outcomes ...
NCI Division of Cancer Prevention
by celsa-spraggs
NCI Division of Cancer Prevention Ongoing Activi...
OVERVIEW OF PROCUREMENT
by mitsue-stanley
PROCESS. Presented By: . Stephen Davis, Contracti...
PARP Inhibitors This program will include a discussion of off-label treatment and investigational a
by conchita-marotz
PARP Inhibitors: What Do We know?. PARP Inhibitor...
Precision Medicine Clinical Trial Designs
by luanne-stotts
2018 . AACR Annual Meeting. April 15, 2018 . Edwa...
Immuno-Oncology Translational Network (IOTN)
by luanne-stotts
Pre-Application Webinar. RFA-CA-19-015: Cancer Im...
Precision Oncology Carolyn M. Hutter, PhD
by lindy-dunigan
1. 2015 Precision Medicine Initiative: . Two Comp...
Supported Decision Making Demonstration Project
by lois-ondreau
: . A . Collaborative . Approach ....
Cancer Unknown Primary Sarah W. Gordon, DO
by olivia-moreira
Assistant Professor. Virginia Commonwealth Univer...
Consolidated financial statements
by alida-meadow
Prepared by: Michael Wells. Date: June 13-17, 201...
Load More...